Thrombosis and Embolism After Injury J Clin Pathol: First Published As 10.1136/Jcp.S3-4.1.86 on 1 January 1970
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Disseminated Intravascular Coagulation (DIC) and Thrombosis: the Critical Role of the Lab Paul Riley, Phd, MBA, Diagnostica Stago, Inc
Generate Knowledge Disseminated Intravascular Coagulation (DIC) and Thrombosis: The Critical Role of the Lab Paul Riley, PhD, MBA, Diagnostica Stago, Inc. Learning Objectives Describe the basic pathophysiology of DIC Demonstrate a diagnostic and management approach for DIC Compare markers of thrombin & plasmin generation in DIC, including D-Dimer, fibrin monomers (FM; aka soluble fibrin monomers, SFM), and fibrin degradation products (FDPs; aka fibrin split products, FSPs) Correlate DIC theory and testing to specific clinical cases DIC = Death is Coming What is Hemostasis? Blood Circulation Occurs through blood vessels ARTERIES The heart pumps the blood Arteries carry oxygenated blood away from the heart under high pressure VEINS Veins carry de-oxygenated blood back to the heart under low pressure Hemostasis The mechanism that maintains blood fluidity Keeps a balance between bleeding and clotting 2 major roles Stop bleeding by repairing holes in blood vessels Clean up the inside of blood vessels Removes temporary clot that stopped bleeding Sweeps off needless deposits that may cause blood flow blockages Two Major Diseases Linked to Hemostatic Abnormalities Bleeding = Hemorrhage Blood clot = Thrombosis Physiology of Hemostasis Wound Sealing break in vesselEFFRAC PRIMARY PLASMATIC HEMOSTASIS COAGULATION strong clot wound sealing blood FIBRINOLYSIS flow ± stopped clot destruction The Three Steps of Hemostasis Primary Hemostasis Interaction between vessel wall, platelets and adhesive proteins platelet clot Coagulation Consolidation -
Heart – Thrombus
Heart – Thrombus Figure Legend: Figure 1 Heart, Atrium - Thrombus in a male Swiss Webster mouse from a chronic study. A thrombus is present in the right atrium (arrow). Figure 2 Heart, Atrium - Thrombus in a male Swiss Webster mouse from a chronic study (higher magnification of Figure 1). Multiple layers of fibrin, erythrocytes, and scattered inflammatory cells (arrows) comprise this right atrial thrombus. Figure 3 Heart, Atrium - Thrombus in a male Swiss Webster mouse from a chronic study. A large thrombus with two foci of mineral fills the left atrium (arrow). Figure 4 Heart, Atrium - Thrombus in a male Swiss Webster mouse from a chronic study (higher magnification of Figure 3). This thrombus in the left atrium (arrows) has two dark, basophilic areas of mineral (arrowheads). 1 Heart – Thrombus Comment: Although thrombi can be seen in the right (Figure 1 and Figure 2) or left (Figure 3 and Figure 4) atrium, the most common site of spontaneously occurring and chemically induced thrombi is the left atrium. In acute situations, the lumen is distended by a mass of laminated fibrin layers, leukocytes, and red blood cells. In more chronic cases, there is more organization of the thrombus (e.g., presence of vascularized fibrous connective tissue, inflammation, and/or cartilage metaplasia), with potential attachment to the atrial wall. Spontaneous rates of cardiac thrombi were determined for control Fischer 344 rats and B6C3F1 mice: in 90-day studies, 0% in rats and mice; in 2-year studies, 0.7% in both genders of mice, 4% in male rats, and 1% in female rats. -
Thrombotic Thrombocytopenic Purpura
Thrombotic thrombocytopenic Purpura Flora Peyvandi Angelo Bianchi Bonomi Hemophilia and Thrombosis Center IRCCS Ca’ Granda Ospedale Maggiore Policlinico University of Milan Milan, Italy Disclosures Research Support/P.I. No relevant conflicts of interest to declare Employee No relevant conflicts of interest to declare Consultant Kedrion, Octapharma Major Stockholder No relevant conflicts of interest to declare Speakers Bureau Shire, Alnylam Honoraria No relevant conflicts of interest to declare Scientific Advisory Ablynx, Shire, Roche Board Objectives • Advances in understanding the pathogenetic mechanisms and the resulting clinical implications in TTP • Which tests need to be done for diagnosis of congenital and acquired TTP • Standard and novel therapies for congenital and acquired TTP • Potential predictive markers of relapse and implications on patient management during remission Thrombotic Thrombocytopenic Purpura (TTP) First described in 1924 by Moschcowitz, TTP is a thrombotic microangiopathy characterized by: • Disseminated formation of platelet- rich thrombi in the microvasculature → Tissue ischemia with neurological, myocardial, renal signs & symptoms • Platelets consumption → Severe thrombocytopenia • Red blood cell fragmentation → Hemolytic anemia TTP epidemiology • Acute onset • Rare: 5-11 cases / million people / year • Two forms: congenital (<5%), acquired (>95%) • M:F ratio 1:3 • Peak of incidence: III-IV decades • Mortality reduced from 90% to 10-20% with appropriate therapy • Risk of recurrence: 30-35% Peyvandi et al, Haematologica 2010 TTP clinical features Bleeding 33 patients with ≥ 3 acute episodes + Thrombosis “Old” diagnostic pentad: • Microangiopathic hemolytic anemia • Thrombocytopenia • Fluctuating neurologic signs • Fever • Renal impairment ScullyLotta et et al, al, BJH BJH 20122010 TTP pathophysiology • Caused by ADAMTS13 deficiency (A Disintegrin And Metalloproteinase with ThromboSpondin type 1 motifs, member 13) • ADAMTS13 cleaves the VWF subunit at the Tyr1605–Met1606 peptide bond in the A2 domain Furlan M, et al. -
32 Mechanism of Thrombosis in Antiphospholipid Syndrome: Binding to Platelets Joan-Carles Reverter and Dolors Tàssies
32 Mechanism of Thrombosis in Antiphospholipid Syndrome: Binding to Platelets Joan-Carles Reverter and Dolors Tàssies Introduction Antiphospholipid antibodies (aPL) are related to thrombosis in the antiphospho- lipid syndrome (APS) [1, 2] and numerous pathophysiological mechanisms have been suggested involving cellular effects, plasma coagulation regulatory proteins, and fibrinolysis [3, 4]: aPL may act as blocking agents directly inhibiting antigen enzymatic or co-factor function of hemostasis; may bind fluid-phase antigens of hemostasis involved proteins and then decrease plasma antigen levels by clearance of immune complexes; may form immune complexes with their antigens that may be deposited in blood vessels causing inflammation and tissue injury; may cause dysregulation of antigen–phospholipid binding due to cross-linking of membrane bound antigens; and may trigger cell mediated events by cross-linking of antigen bound to cell surfaces or cell surface receptors [3, 4]. Moreover, several characteris- tics of the aPL, such as the concentration, class/subclass, affinity or charge, and several characteristics of the antigens, as the concentration, size, location or charge, may influence which of the theoretical autoantibody actions will occur in vivo [3]. Among the cellular mechanisms supposed to be involved, platelets have been considered as one of the most promising potential target for circulating aPL that may cause antibody mediated thrombosis as a part of the clinical spectrum of the autoimmune disorder of the APS. In the present chapter we will focus on the inter- actions that involve aPL binding to platelet membrane or platelet membrane bound antigens. Platelets as Target for aPL Platelets play a central role in primary hemostasis involving platelet adhesion to the injured blood vessel wall, followed by platelet activation, granule release, shape change, and rearrangement of the outer membrane phospholipids and proteins, transforming them into a highly efficient procoagulant surface [5]. -
What Is Dvt? Deep Vein Thrombosis (DVT) Occurs When an Abnormal Blood Clot Forms in a Large Vein
What is DVt? Deep vein thrombosis (DVT) occurs when an abnormal blood clot forms in a large vein. These clots usually develop in the lower leg, thigh, or pelvis, but can also occur in other large veins in the body. If you develop DVT and it is diagnosed correctly and quickly, it can be treated. However, many people do not know if they are at risk, don’t know the symptoms, and delay seeing a healthcare professional if they do have symptoms. CAn DVt hAppen to me? Anyone may be at risk for DVT but the more risk factors you have, the greater your chances are of developing DVT. Knowing your risk factors can help you prevent DVt: n Hospitalization for a medical illness n Recent major surgery or injury n Personal history of a clotting disorder or previous DVT n Increasing age this is serious n Cancer and cancer treatments n Pregnancy and the first 6 weeks after delivery n Hormone replacement therapy or birth control products n Family history of DVT n Extended bed rest n Obesity n Smoking n Prolonged sitting when traveling (longer than 6 to 8 hours) DVt symptoms AnD signs: the following are the most common and usually occur in the affected limb: n Recent swelling of the limb n Unexplained pain or tenderness n Skin that may be warm to the touch n Redness of the skin Since the symptoms of DVT can be similar to other conditions, like a pulled muscle, this often leads to a delay in diagnosis. Some people with DVT may have no symptoms at all. -
A 12-Years Rectal Bleeding Complicated with Deep Vein Thrombosis, Is Hemorrhoid the Real Cause?
Case Report Clinical Case Reports Volume 10:11, 2020 DOI: 10.37421/jccr.2020.10.1395 ISSN: 2165-7920 Open Access A 12-Years Rectal Bleeding Complicated with Deep Vein Thrombosis, Is Hemorrhoid the Real Cause? Yi-Qun Zhang, Meng Niu and Chun-Xiao Chen* Department of Gastroenterology, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, P. R. China Abstract Colorectal venous malformation is a rare condition that can cause massive rectal bleeding. This is the first report of colorectal venous malformation complicated with massive bleeding and lowers limb deep vein thrombosis, and the two life-threatening conditions were both treated successfully. Keywords: Colorectal venous malformation • Rectal bleeding • Sclerotherapy • Deep vein thrombosis Introduction A 16-year-old man presented to the clinic with long-standing recurrent hematochezia and profound anemia. Per the mother, his rectal bleeding was first noticed around the age of 4 with one episode per 2-3 months that was diagnosed as hemorrhoids without specific treatment. It had worsened for 2 months with progression to 1 bloody bowel movement daily. He had no family history of hematologic disorders or vascular anomalies. The patient had accepted 600 ml red-blood cell perfusion and intravenous sucrose-iron transfusions for severe anemia with hemoglobin 5.8 g/dL, hematocrit 25.9% and MCV 69.7 fL at local hospital. Case Report Upon admission, the patient’s vital signs were within normal limits. His abdomen was supple and without tenderness. Digital rectal examination confirmed partially thrombosed, circumferential mixed hemorrhoids. Laboratory tests revealed a hemoglobin 8.0 g/L and D-dimer 15760 g/L. -
Hypertension and the Prothrombotic State
Journal of Human Hypertension (2000) 14, 687–690 2000 Macmillan Publishers Ltd All rights reserved 0950-9240/00 $15.00 www.nature.com/jhh REVIEW ARTICLE Hypertension and the prothrombotic state GYH Lip Haemostasis Thrombosis and Vascular Biology Unit, University Department of Medicine, City Hospital, Birmingham, UK The basic underlying pathophysiological processes related to conventional risk factors, target organ dam- underlying the major complications of hypertension age, complications and long-term prognosis, as well as (that is, heart attacks and strokes) are thrombogenesis different antihypertensive treatments. Further work is and atherogenesis. Indeed, despite the blood vessels needed to examine the mechanisms leading to this being exposed to high pressures in hypertension, the phenomenon, the potential prognostic and treatment complications of hypertension are paradoxically throm- implications, and the possible value of measuring these botic in nature rather than haemorrhagic. The evidence parameters in routine clinical practice. suggests that hypertension appears to confer a Journal of Human Hypertension (2000) 14, 687–690 prothrombotic or hypercoagulable state, which can be Keywords: hypercoagulable; prothrombotic; coagulation; haemorheology; prognosis Introduction Indeed, patients with hypertension are well-recog- nised to demonstrate abnormalities of each of these Hypertension is well-recognised to be an important 1 components of Virchow’s triad, leading to a contributor to heart attacks and stroke. Further- prothrombotic or hypercoagulable state.4 Further- more, effective antihypertensive therapy reduces more, the processes of thrombogenesis and athero- strokes by 30–40%, and coronary artery disease by 2 genesis are intimately related, and many of the basic approximately 25%. Nevertheless the basic under- concepts thrombogenesis can be applied to athero- lying pathophysiological processes underlying both genesis. -
Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE)
How can it be prevented? You can take steps to prevent deep vein thrombosis (DVT) and pulmonary embolism (PE). If you're at risk for these conditions: • See your doctor for regular checkups. • Take all medicines as your doctor prescribes. • Get out of bed and move around as soon as possible after surgery or illness (as your doctor recommends). Moving around lowers your chance of developing a blood clot. References: • Exercise your lower leg muscles during Deep Vein Thrombosis: MedlinePlus. (n.d.). long trips. Walking helps prevent blood Retrieved October 18, 2016, from clots from forming. https://medlineplus.gov/deepveinthrombos is.html If you've had DVT or PE before, you can help prevent future blood clots. Follow the steps What Are the Signs and Symptoms of Deep above and: Vein Thrombosis? - NHLBI, NIH. (n.d.). Retrieved October 18, 2016, from • Take all medicines that your doctor http://www.nhlbi.nih.gov/health/health- prescribes to prevent or treat blood clots topics/topics/dvt/signs • Follow up with your doctor for tests and treatment Who Is at Risk for Deep Vein Thrombosis? - • Use compression stockings as your DEEP NHLBI, NIH. (n.d.). Retrieved October 18, doctor directs to prevent leg swelling 2016, from http://www.nhlbi.nih.gov/health/health- VEIN topics/topics/dvt/atrisk THROMBOSIS How Can Deep Vein Thrombosis Be Prevented? - NHLBI, NIH. (n.d.). Retrieved October 18, 2016, from (DVT) http://www.nhlbi.nih.gov/health/health- topics/topics/dvt/prevention How Is Deep Vein Thrombosis Treated? - NHLBI, NIH. (n.d.). Retrieved October 18, 2016, from http://www.nhlbi.nih.gov/health/health- topics/topics/dvt/treatment Trinity Surgery Center What is deep vein Who is at risk? What are the thrombosis (DVT)? The risk factors for deep vein thrombosis symptoms? (DVT) include: Only about half of the people who have DVT A blood clot that forms in a vein deep in the • A history of DVT. -
Zebrafish Depends on Von Willebrand Factor
Hemostasis ARTICLE Histone-induced thrombotic thrombocytopenic Ferrata Storti Foundation purpura in adamts13-/- zebrafish depends on von Willebrand factor Liang Zheng,1 Mohammad S. Abdelgawwad,1 Di Zhang,1 Leimeng Xu,1 Shi Wei,2 Wenjing Cao1 and X. Long Zheng1 Divisions of 1Laboratory Medicine and 2Anatomic Pathology, Department of Pathology, The University of Alabama at Birmingham, Birmingham, AL, USA ABSTRACT Haematologica 2020 Volume 105(4):1107-1119 hrombotic thrombocytopenic purpura (TTP) is caused by severe deficiency of ADAMTS13 (A13), a plasma metalloprotease that Tcleaves endothelium-derived von Willebrand factor (VWF). However, severe A13 deficiency alone is often not sufficient to cause an acute TTP; additional factors may be required to trigger the disease. Using CRISPR/Cas9, we created and characterized several novel zebrafish lines carrying a null mutation in a13-/-, vwf, and both. We fur- ther used these zebrafish lines to test the hypothesis that inflammation that results in neutrophil activation and release of histone/DNA com- plexes may trigger TTP. As shown, a13-/- zebrafish exhibit increased lev- els of plasma VWF antigen, multimer size, and ability of thrombocytes to adhere to a fibrillar collagen-coated surface under flow. The a13-/- zebrafish also show an increased rate of occlusive thrombus formation in -/- the caudal venules after FeCl3 injury. More interestingly, a13 zebrafish exhibit ~30% reduction in the number of total, immature, and mature thrombocytes with increased fragmentation of erythrocytes. Administration of a lysine-rich histone results in more severe and persist- Correspondence: ent thrombocytopenia and a significantly increased mortality rate in a13-/- zebrafish than in wildtype (wt) ones. However, both spontaneous and X. -
Deep Vein Thrombosis (DVT)
Diseases and Conditions Deep vein thrombosis (DVT) By Mayo Clinic Staff Deep vein thrombosis (DVT) occurs when a blood clot (thrombus) forms in one or more of the deep veins in your body, usually in your legs. Deep vein thrombosis can cause leg pain or swelling, but may occur without any symptoms. Deep vein thrombosis can develop if you have certain medical conditions that affect how your blood clots. Deep vein thrombosis can also happen if you don't move for a long time, such as after surgery, following an accident, or when you are confined to a hospital or nursing home bed. Deep vein thrombosis is a serious condition because blood clots in your veins can break loose, travel through your bloodstream and lodge in your lungs, blocking blood flow (pulmonary embolism). Deep vein thrombosis signs and symptoms can include: Swelling in the affected leg. Rarely, there may be swelling in both legs. Pain in your leg. The pain often starts in your calf and can feel like cramping or a soreness. Deep vein thrombosis may sometimes occur without any noticeable symptoms. When to see a doctor If you develop signs or symptoms of deep vein thrombosis, contact your doctor for guidance. If you develop signs or symptoms of a pulmonary embolism — a life-threatening complication of deep vein thrombosis — seek medical attention immediately. The warning signs of a pulmonary embolism include: Unexplained sudden onset of shortness of breath Chest pain or discomfort that worsens when you take a deep breath or when you cough Feeling lightheaded or dizzy, or fainting Rapid pulse Coughing up blood Deep vein thrombosis occurs when a blood clot forms in the veins that are deep in your body, often in your legs. -
(I): Diagnosis, Treatment and Prognosis of Budd-Chiari Syndrome
rEViEW Vascular liver disorders (i): diagnosis, treatment and prognosis of budd-Chiari syndrome J. Hoekstra, H.L.A. Janssen* Department of Gastroenterology and Hepatology, Erasmus Medical Center, University Medical Center Rotterdam, PO Box 2040, 3000 CA Rotterdam, the Netherlands, *corresponding author: room Ha 206, tel.: +31 (0)10-703 59 42, fax: +31 (0)10-436 59 16, e-mail: [email protected] AbsTract IntroductioN budd-Chiari syndrome (bCs) is a venous outflow obstruction Thrombosis involving the liver vasculature is rare but of the liver that has a dismal outcome if left untreated. Most constitutes a potentially life-threatening situation. cases of bCs in the Western world are caused by thrombosis of Budd-Chiari syndrome (BCS) is characterised by the hepatic veins, sometimes in combination with thrombosis thrombosis of the hepatic outflow tract. It is defined of the inferior vena cava. Typical presentation consists as a venous obstruction that can be located from the of abdominal pain, hepatomegaly and ascites, although level of the small hepatic veins up to the junction of the symptoms may vary significantly. Currently, a prothrombotic inferior vena cava with the right atrium (figure 1).1 Hepatic risk factor, either inherited or acquired, can be identified in outflow obstruction related to right-sided cardiac failure the majority of patients. Moreover, in many patients with bCs or sinusoidal obstruction syndrome (SOS, also known as a combination of risk factors is present. Myeloproliferative veno-occlusive disease)2 is not included in the definition of disorders are the most frequent underlying cause, occurring BCS. The clinical symptoms of BCS were first described by in approximately half of the patients. -
Chapter 6: Clinical Presentation of Venous Thrombosis “Clots”
CHAPTER 6 CLINICAL PRESENTATION OF VENOUS THROMBOSIS “CLOTS”: DEEP VENOUS THROMBOSIS AND PULMONARY EMBOLUS Original authors: Daniel Kim, Kellie Krallman, Joan Lohr, and Mark H. Meissner Abstracted by Kellie R. Brown Introduction The body has normal processes that balance between clot formation and clot breakdown. This allows clot to form when necessary to stop bleeding, but allows the clot formation to be limited to the injured area. Unbalancing these systems can lead to abnormal clot formation. When this happens clot can form in the deep veins usually, but not always, in the legs, forming a deep vein thrombosis (DVT). In some cases, this clot can dislodge from the vein in which it was formed and travel through the bloodstream into the lungs, where it gets stuck as the size of the vessels get too small to allow the clot to go any further. This is called a pulmonary embolus (PE). This limits the amount of blood that can get oxygen from the lungs, which then limits the amount of oxygen that can be delivered to the rest of the body. How severe the PE is for the patient has to do with the size of the clot that gets to the lungs. Small clots can cause no symptoms at all. Very large clots can cause death very quickly. This chapter will describe the symptoms that are caused by DVT and PE, and discuss the means by which these conditions are diagnosed. What are the most common signs and symptoms of a DVT? The symptoms that are caused by DVT depend on the location and extent of the clot.